2020
FluoGuide’s strategic development plan centers on advancing its lead product, FG001, for targeted glioblastoma surgery, and on...
The preclinical studies needed to support human clinical trials for FG001 have now been completed and reported. The clean outcome of...
30 June, 2020
Dorthe Grønnegaard Mejer joins FluoGuide A/S as Vice President of Clinical Development
The clinical development of FG001 for use to guide surgery of aggressive brain cancer (glioblastoma) can be very short until approval...
8 June, 2020
FluoGuide A/S selected as a top innovator and awarded €2.5 million by the European Innovation Council
FluoGuide is preparing a proof-of-concept clinical study (phase I/IIa) to demonstrate the effect of FG001 in patients with glioblastoma...
”The entire FluoGuide team is working hard to capture the enormous potential of the Company to help patients and benefit shareholders...
FluoGuide has previously communicated its anticipation of a clean outcome of these studies which has now been confirmed. FluoGuide...
27 May, 2020
FluoGuide presents today at Orphan Drugs
Today, 27 May at 11:10 (CEST), FluoGuide’s CEO Morten Albrechtsen presents the company and some of the recent developments...
18 May, 2020
Registration at the Danish Business Authority
Number of shares and share capital
The change of registration procedure for the 27,737 shares does not change the total number of...
18 May, 2020
FluoGuide A/S - Flagging message
FluoGuide A/S (“FluoGuide” or “the Company”) hereby announce that due to dilution in connection to the warrant...